4 December 2013 - Cystic Fibrosis Australia (CFA) can confirm that Kalydeco was discussed at the November meeting ofthe Pharmaceutical Benefits Advisory Committee (PBAC) in response to a minor submission lodgedby Vertex and information provided by CF physicians and CFA.This is very good news and the outcome of this meeting will be made public on 20 December via thePBAC website.Additionally, we can confirm that Vertex lodged a further major submission by the required date forconsideration at the March 2014 PBAC meeting.

For more details, go to: http://www.cysticfibrosis.org.au